Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marathon Looking To Go The Distance In DMD

Executive Summary

The biotech submitted an NDA to FDA for its DMD drug in hopes of succeeding where other companies have failed.

Advertisement

Related Content

Venture Funding Deals: ADC Therapeutics, Unity Biotech Raise $100m-Plus
DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?
Agony & Ecstasy Of Sarepta: A New FDA Rare Disease Standard?
BioMarin Kills Kyndrisa, But Duchenne Pursuit Not Over
Scots Hammer PTC's Translarna As EU Reviews Conditional Approval
FDA Refuses To File Translarna NDA; PTC Plummets

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065418

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel